Guardian Pharmacy Services earnings release, August 6, 2026

Guardian Pharmacy Services, Inc. (GRDN) · Form 8-K, Item 2.02 · Filed · SEC filing

Guardian Pharmacy Services Reports Second Quarter 2026 Financial Results; Raises Full-Year Guidance

ATLANTA, August 6, 2026 – Guardian Pharmacy Services, Inc. (NYSE: GRDN), one of the nation’s leading long-term care

(“LTC”) pharmacy services companies, announced today its financial results for the second quarter ended June 30, 2026. The Company also raised its full-year guidance.

Second Quarter Financial Results

CEO Commentary

“Guardian delivered another strong quarter, with continued momentum across our local markets,” said Fred Burke, President and Chief Executive

Officer. “While

IRA-related pricing reductions affected reported revenue growth, which was up 2%, the underlying business remained strong. Absent the price reductions from the IRA, revenues would have been up low double digits compared to the second quarter of 2025. We also continued to expand profitability, reflecting the benefits of scale, purchasing leverage and improved operating efficiency.”

Burke continued, “Our second-quarter performance, together with our outlook for the remainder of the year, gives us the confidence to raise our 2026 guidance.”

FY 2026 Outlook – Updating Guidance

The guidance below excludes any future acquisitions.

M&A and Greenfields

Subsequent to quarter-end,

Guardian completed the acquisition of Wellness Concepts, a long-term care pharmacy based in

Grottoes, Virginia. Founded in 1999, Wellness Concepts has established a strong reputation for service and quality care throughout the Shenandoah Valley. The pharmacy’s existing leadership and employees will remain in place.

Guardian also launched a new greenfield pharmacy in Lexington, Kentucky, representing the Company’s first location in the state. The pharmacy was developed collaboratively by Guardian’s Tennessee and Cincinnati operations under the leadership of David Brown, one of the Company’s recently appointed regional senior vice presidents.

Lexington represents the fourth greenfield pharmacy developed by this leadership team since joining Guardian through the Company’s Middle Tennessee acquisition in 2009. Together, these investments further expand Guardian’s geographic footprint and demonstrate the Company’s ability to combine local market expertise, acquired talent and disciplined development to support long-term growth.

Leadership and Organizational Updates

As previously announced, Guardian appointed David Morris as Chief Operating Officer and Will Mudd as Chief Financial Officer, effective July 1, 2026. Mr. Morris previously served as Guardian’s Chief Financial Officer and has played a central role in the Company’s development since its inception. In his new role, he will oversee Guardian’s pharmacy operations and sales organization.

Mr. Mudd joined Guardian in 2012 and has held positions of increasing responsibility across the Company’s finance organization. He most recently served as Senior Vice President of Finance and has been instrumental in developing the financial infrastructure that supported Guardian’s growth and transition to becoming a public company. The appointments reflect the depth of

Guardian’s leadership team and support the Company’s continued evolution as it expands its national platform.

In connection with these organizational changes, Guardian also implemented a regional leadership structure led by eight regional senior vice presidents, designed to strengthen accountability, improve coordination and better support local pharmacy teams while preserving the entrepreneurial culture and local decision-making central to Guardian’s operating model.

Conference Call Details

Guardian will host a conference call to discuss these results today at 4:30 pm ET. The call can be accessed live by dialing +1 (833)

461-5787 for participants located in the United States and Canada, or +1 (585)

542-9983 for international participants, and referencing conference ID “153 713

694.” A webcast replay will be available shortly after the call’s completion at https://investors.guardianpharmacy.com

About

Guardian Pharmacy Services

Guardian Pharmacy Services is one of the nation’s leading long-term care pharmacy services companies. Through its locally-based business model, Guardian partners with long-term care facilities (“LTCFs”) to deliver medications and a comprehensive suite of technology-enabled services designed to enhance care and improve adherence to drug regimens, helping to reduce the cost of care and improve clinical outcomes. With a growing network of more than 61 licensed pharmacies, 54 of which are full-service, Guardian is dedicated to providing exceptional service to approximately 210,000 residents (as of June 30, 2026).

Investor Contact:

Ashley Stockton, Vice President, Investor Relations IR@guardianpharmacy.net

Financial statements

Income Statement

Three Months Ended June 30, — (UNAUDITED) (In thousands, except per share amounts)

Three Months Ended June 30, – 2025Three Months Ended June 30, – 2026Six Months Ended June 30, – 2025Six Months Ended June 30, – 2026
Revenues344,334351,768673,642688,363
Cost of goods sold276,188271,724541,147532,010
Gross profit68,14680,044132,495156,353
Selling, general, and administrative expenses55,56659,400106,910118,034
Operating income12,58020,64425,58538,319
Other expenses (income):Interest expense172154342308
Other expenses (income):Other expense (income), net-179-9,302-450-10,074
Other expenses (income):Total other expenses (income)-7-9,148-108-9,766
Other expenses (income):Income before income taxes12,58729,79225,69348,085
Other expenses (income):Provision for income taxes3,7607,6717,59312,420
Other expenses (income):Net income8,82722,12118,10035,665
Other expenses (income):Less net income (loss) attributable to non-controlling interests-203249-378498
Other expenses (income):Net income attributable to Guardian Pharmacy Services, Inc.9,03021,87218,47835,167
Net income per share of Class A and Class B common stockBasic0.150.350.30.56
Net income per share of Class A and Class B common stockDiluted0.140.340.290.55
Weighted-average Class A and Class B common shares outstandingBasic62,04663,32762,04563,324
Weighted-average Class A and Class B common shares outstandingDiluted63,20363,83663,05563,757

Income Statement

Three Months Ended June 30, — (UNAUDITED) (in thousands)

Three Months Ended June 30, – 2025Three Months Ended June 30, – 2026Six Months Ended June 30, – 2025Six Months Ended June 30, – 2026
Net income8,82722,12118,10035,665
Add:Interest expense (income), net-68-504-70-920
Add:Depreciation and amortization5,4895,80810,75611,784
Add:Provision for income taxes3,7607,6717,59312,420
Add:EBITDA18,00835,09636,37958,949
Add:Share-based compensation (1)4,4462,9328,4144,793
Add:Certain legal & other regulatory matters (2)5958962318
Add:Financing-related and other activities (3)1,016321,814873
Add:Payor-reimbursement matters (4)887-8,4911,155-5,217
Add:Adjusted EBITDA24,95229,65848,38559,416
Add:Net income as a percentage of revenue2.6%6.3%2.7%5.2%
Add:Adjusted EBITDA as a percentage of revenue7.2%8.4%7.2%8.6%
Add:Net Income attributable to Guardian Pharmacy Services, Inc.9,03021,87218,47835,167
Add:Share-based compensation (1)4,4462,9328,4144,793
Add:Certain legal & other regulatory matters (2)5958962318
Add:Financing-related and other activities (3)1,016321,814873
Add:Payor-reimbursement matters (4)887-8,4911,155-5,217
Add:Acquisition-related intangible asset amortization (5)8748651,7091,857
Add:Income tax impact of adjustments (6)-2,3141,175-2,866-600
Add:Adjusted net income14,53418,47429,32736,891
Add:Weighted average common shares outstanding used in calculating diluted U.S. GAAP net income per share63,20363,83663,05563,757
Add:Weighted average common shares outstanding used in calculating diluted Non-GAAP net income per share63,20363,83663,05563,757
Add:Diluted EPS0.140.340.290.55
Add:Adjusted EPS0.230.290.470.58

Balance Sheet

December 31, 2025 — (UNAUDITED) (In thousands, except share amounts)

December 31, 2025June 30, 2026
Current assets:Cash and cash equivalents65,61989,807
Current assets:Accounts receivable, net101,614103,769
Current assets:Inventories43,35950,442
Current assets:Other current assets11,04210,650
Current assets:Total current assets221,634254,668
Current assets:Property and equipment, net55,52256,529
Current assets:Intangible assets, net18,47516,619
Current assets:Goodwill79,74379,743
Current assets:Operating lease right-of-use assets34,64932,361
Current assets:Deferred tax assets2,1992,199
Current assets:Other assets4361,459
Current assets:Total assets412,658443,578
Current liabilities:Accounts payable116,206108,207
Current liabilities:Accrued compensation15,04815,090
Current liabilities:Operating leases, current portion7,1507,375
Current liabilities:Other current liabilities22,29923,371
Current liabilities:Total current liabilities160,703154,043
Current liabilities:Operating leases, net of current portion29,99227,863
Current liabilities:Other liabilities4,0394,030
Current liabilities:Total liabilities194,734185,936
Equity:Class A common stock - 700,000,000 shares authorized, par value $0.001; 36,253,744 and 49,792,884 shares issued and outstanding as of December 31, 2025 and June 30, 2026, respectively3650
Equity:Class B common stock - 100,000,000 shares authorized, par value $0.001; 27,066,890 and 13,539,453 shares issued and outstanding as of December 31, 2025 and June 30, 2026, respectively2713
Equity:Additional paid-in capital139,353144,040
Equity:Retained earnings66,343101,510
Equity:Non-controlling interests12,16512,029
Equity:Total equity217,924257,642
Equity:Total liabilities and equity412,658443,578

Cash Flow

Six Months Ended June, 30 — CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (in thousands)

Six Months Ended June, 30 – 2025Six Months Ended June, 30 – 2026
Operating activitiesNet income18,10035,665
Full release

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements are all statements other than those of historical fact. Any statements about our expectations, beliefs, plans, predictions, forecasts, objectives, assumptions, or future events or performance are not historical facts and are forward-looking. These statements are often, but not always, made through the use of words such as

“aims,” “anticipates,” “believes,” “continue,” “estimates,” “expects,” “intends,” “may,” “outlook,” “plans,”

“projects,” “seeks,” “should,” “will,” “would,” and similar expressions. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements are not guarantees of future performance and involve risks and uncertainties which are subject to change based on various important factors, many of which are beyond our control. Such risks and uncertainties include: our ability to... (truncated)ctively market and sell, customer acceptance of, and competition for, our pharmaceutical and health care services in new and existing markets; our relationships with pharmaceutical wholesalers and key manufacturers, LTCFs and health plan payors; our ability to maintain and expand relationships with LTCF operators on favorable terms; our ability to identify, complete and successfully integrate acquisitions; the impact of a national emergency, public health crisis, global pandemic or outbreak of infectious disease on our employees, business, supply chain and the LTCFs we serve; continuing government and private efforts to lower pharmaceutical costs, including by capping the prices for certain drugs and limiting pharmacy reimbursements; changes in, and our ability to comply with, healthcare and other applicable laws, regulations or interpretations; further consolidation of managed care organizations and other health plan payors and changes in the terms of our agreements with these parties; our ability to retain members of our senior management team, our local pharmacy management teams and our pharmacy professionals; our exposure to, and the results of, claims, legal proceedings and governmental inquiries; our ability to maintain the security and integrity of our operating and information technology systems and infrastructure (e.g., against cyber-attacks); product liability, product recall, personal injury or other health and safety issues related to the pharmaceuticals we dispense; the impact of supply chain and other manufacturing disruptions or trade policies related to the pharmaceuticals we dispense; the sufficiency of our sources of liquidity and financial resources to fund our future operating expenses and capital expenditure requirements, and our ability to raise additional capital, if needed; and the misuse or off-label use, or errors in the dispensing or administration, of the pharmaceuticals we dispense. We are subject to additional risks and uncertainties described in our periodic reports filed with the Securities and Exchange Commission from time to time, including in the “Risk Factors” section contained in our most recent Annual Report on Form

10-K, which report is publicly available at www.sec.gov and via our website, investors.guardianpharmacy.com. Any forward-looking statements in this press release should be evaluated in light of these important risk factors. This press release reflects management’s views as of the date hereof. Except to the extent required by applicable law, Guardian undertakes no obligation to update or revise any information contained in this press release beyond the published date, whether as a result of new information, future events or otherwise.

Additional Information

This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent Annual Report on

Form

10-K,

Quarterly Report on Form

10-Q and subsequent filings. Copies of our reports are available on our website at no expense at investors.guardianpharmacy.com and through the SEC’s website at www.sec.gov.

Use of

Non-GAAP

Financial Measures

To supplement the results presented in our consolidated financial statements in accordance with GAAP, we also present Adjusted EBITDA, Adjusted

Net Income, and Adjusted EPS, which are financial measures not based on any standardized methodology prescribed by GAAP.

We define

Adjusted EBITDA as net income before interest expense (income), income taxes, depreciation and amortization, as adjusted to exclude the impact of items and amounts that we view as not indicative of our core operating performance, including share-based compensation, certain legal and regulatory items, financing-related and other activities, and payor-reimbursement matters.

We define Adjusted Net Income as net income attributable to Guardian Pharmacy Services, Inc. before share-based compensation expense, certain legal and other regulatory items, financing-related and other activities, payor-reimbursement matters, amortization expense associated with acquisition-related intangible assets, and the income tax impact of the adjustments.

We define

Adjusted EPS as Adjusted Net Income divided by the total weighted average of diluted shares for Class A common stock and Class B common stock.

Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS do not have a definition under GAAP, and our definition of Adjusted EBITDA, Adjusted

Net Income, and Adjusted EPS may not be the same as, or comparable to, similarly titled measures used by other companies.

We use Adjusted

EBITDA, Adjusted Net Income, and Adjusted EPS to better understand and evaluate our core operating performance and trends. We believe that presenting Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS provides useful information to investors in understanding and evaluating our operating results, as it permits investors to view our core business performance using the same metrics that management uses to evaluate our performance.

There are a number of limitations related to the use of Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS rather than the most directly comparable GAAP financial measure, including:

Because of these limitations, Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. You should consider Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS alongside other financial measures, including net income, diluted EPS, and our other financial results presented in accordance with GAAP.

A reconciliation of Adjusted EBITDA to net income and of Adjusted Net Income to Net Income Attributable to Guardian Pharmacy Services, Inc., the most directly comparable GAAP financial measures, are set forth below.

Guardian has not provided a quantitative reconciliation of... (trud adjusted EBITDA to forecasted net income within this release because Guardian is unable, without making unreasonable efforts, to calculate certain reconciling items with confidence due to the variability and complexity of such items.

These items include, but are not limited to, income taxes and share-based compensation. These items, which could materially affect the computation of forecasted net income, are inherently uncertain and depend on various factors that are not estimable at this time.

GUARDIAN PHARMACY SERVICES, INC. AND SUBSIDIARIES

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Guardian Pharmacy Services earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.